DNLI Institutional Ownership

Denali Therapeutics Inc.

Latest close $24.17 as of Aug 4, 2026

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing Jul 8, 2026

Public consensus preview Broad accumulation 88/100 institutional research score

Multi-institution accumulation 5 tracked institutions Latest filing Jul 8, 2026

2 accumulating across 2 comparable institutions.

Accumulating2

Unchanged0

Reducing0

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$12.58 52-week high$26.36

Latest close $24.17 84.1% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Jun 30, 2026

T. Rowe Price Investment Management Jul 8, 2026 filed

Capital Research Global Investors Feb 13, 2025 filed

Fidelity / FMR May 6, 2026 filed

BlackRock Nov 8, 2024 filed

BlackRock Legacy Jan 25, 2024 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 9 parsed filing(s) · 6 older require more history access

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
T. Rowe Price Investment Management CIK0001897612	Jun 30, 2026 observed Jul 8, 2026 filed · 8d Schedule 13G amendment	Reported accumulation	16.2M +7.7M	12.00% 0.00 pts	$25.72	$26.69	$24.17
T. Rowe Price Investment Management CIK0001897612	Mar 31, 2026 observed May 15, 2026 filed · 45d Initial Schedule 13G	Initial Schedule 13G	8.5M	12.00%	$19.20	$18.62	$24.17
Fidelity / FMR CIK0000315066	Mar 31, 2026 observed May 6, 2026 filed · 36d Schedule 13G amendment	Earliest Schedule 13G amendment found	6.7K	12.00%	$19.20	$20.41	$24.17

Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

RXRX RECURSION PHARMACEUTICALS-A 88/100 Broad accumulation ALGT ALLEGIANT TRAVEL CO 88/100 Broad accumulation CVNA CARVANA CO 88/100 Broad accumulation DOCN DIGITALOCEAN HOLDINGS INC 88/100 Broad accumulation

Recent multi-institution accumulation

TVTX Travere Therapeutics, Inc. 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026